| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Articles |
Departments of Biochemistry (J.L.S.-Q., S.B., J.O.-L.) and Endocrinology and Nutrition (A.P., A.C., M.R.), Hospital de la Santa Creu i Sant Pau, and Department of Biochemistry and Molecular Biology (J.O.-L.), Universitat Autónoma de Barcelona, Barcelona 08025, Spain
Address correspondence and requests for reprints to: Jordi Ordóñez-Llanos, M.D., Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, C/. Antoni María Claret 167, Barcelona 08025, Spain. E-mail: 2038{at}hsp santpau.es.
Abstract
The effect of insulin therapy on low-density lipoprotein (LDL) oxidizability, proportion of electronegative LDL [LDL(-)] and LDL composition was studied in 33 type 2 diabetic patients. Before glycemic control improvement, type 2 diabetic subjects presented higher triglyceride and very low-density lipoprotein cholesterol and lower high-density lipoprotein cholesterol than 25 healthy matched subjects. Furthermore, their LDL was more susceptible to oxidation (lag phase 45.9 ± 5.4 min vs. 49.7 ± 7.6 min, P < 0.05), contained a higher proportion of LDL(-) (19.0 ± 8.7% vs. 14.3 ± 5.5%, P < 0.05), and was enriched in triglyceride and depleted in cholesterol and phopholipids. Lipoprotein profile improved after glycemic optimization but failed to change either LDL oxidizability (45.3 ± 6.2 min) or LDL(-) (17.9 ± 8.2%). These data suggest that oxidation rather than nonenzymatic glycosylation could be related to the high LDL(-) found in these patients and disagree with results obtained in a previous study of type 1 diabetic patients. A second study was conducted in 10 type 1 and 10 type 2 diabetic subjects under insulin therapy, and the proportions of glycated LDL (gLDL) and LDL(-) were determined. Basal gLDL (2.8 ± 0.6%) and LDL(-) (20.7 ± 6.1%) decreased in type 1 diabetics after glycemic optimization (1.9 ± 0.6% and 15.4 ± 3.4%, respectively; P < 0.05). In type 2 patients, even though gLDL decreased (from 2.2 ± 0.6% to 1.6 ± 0.6%, P < 0.05) no effect was observed on LDL(-) (from 17.3 ± 2.9% to 16.0 ± 4.3%). We conclude that nonenzymatic glycosylation, which appears as a determinant of the high proportion of LDL(-) in type 1 diabetes, does not play a major role in LDL(-) generation in type 2 diabetes.
This article has been cited by other articles:
![]() |
D. Mafra, F. R. Santos, J. C. Lobo, D. de Mattos Grosso, A. L. Barreira, L. G. C. Velarde, D. S. P. Abdalla, and M. Leite Jr Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1587 - 1592. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lu, J.-H. Yang, A. R. Burns, H.-H. Chen, D. Tang, J. P. Walterscheid, S. Suzuki, C.-Y. Yang, T. Sawamura, and C.-H. Chen Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1: A Possible Mechanism of Endothelial Apoptosis Circ. Res., March 13, 2009; 104(5): 619 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bancells, S. Benitez, M. Jauhiainen, J. Ordonez-Llanos, P. T. Kovanen, S. Villegas, J. L. Sanchez-Quesada, and K. Oorni High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level J. Lipid Res., March 1, 2009; 50(3): 446 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Gaubatz, B. K. Gillard, J. B. Massey, R. C. Hoogeveen, M. Huang, E. E. Lloyd, J. L. Raya, C.-y. Yang, and H. J. Pownall Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2 J. Lipid Res., February 1, 2007; 48(2): 348 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhang, T. Kaneshi, T. Ohta, and K. Saku Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis J. Lipid Res., October 1, 2005; 46(10): 2265 - 2277. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Veiraiah Hyperglycemia, Lipoprotein Glycation, and Vascular Disease Angiology, July 1, 2005; 56(4): 431 - 438. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |